TWI387463B - Ｉｇｅ ｃｈ３肽疫苗 - Google Patents

Ｉｇｅ ｃｈ３肽疫苗 Download PDF

Info

Publication number
TWI387463B
TWI387463B TW098141914A TW98141914A TWI387463B TW I387463 B TWI387463 B TW I387463B TW 098141914 A TW098141914 A TW 098141914A TW 98141914 A TW98141914 A TW 98141914A TW I387463 B TWI387463 B TW I387463B
Authority
TW
Taiwan
Prior art keywords
seq
composition
group
amino acid
antigenic ige
Prior art date
Application number
TW098141914A
Other languages
English (en)
Chinese (zh)
Other versions
TW201036632A (en
Inventor
Alan Daniel Brown
Brian Robert Champion
Clare Christy
David Paul Gervais
Lyn Howard Jones
Anne Maria Kristina Kjerrstrom
David Cameron Pryde
Lee Richard Roberts
David Michael Wyatt
Original Assignee
Pfizer Vaccines Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42035836&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI387463(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Vaccines Llc filed Critical Pfizer Vaccines Llc
Publication of TW201036632A publication Critical patent/TW201036632A/zh
Application granted granted Critical
Publication of TWI387463B publication Critical patent/TWI387463B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW098141914A 2008-12-09 2009-12-08 Ｉｇｅ ｃｈ３肽疫苗 TWI387463B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12098908P 2008-12-09 2008-12-09

Publications (2)

Publication Number Publication Date
TW201036632A TW201036632A (en) 2010-10-16
TWI387463B true TWI387463B (zh) 2013-03-01

Family

ID=42035836

Family Applications (1)

Application Number Title Priority Date Filing Date
TW098141914A TWI387463B (zh) 2008-12-09 2009-12-08 Ｉｇｅ ｃｈ３肽疫苗

Country Status (21)

Country Link
US (3) US8298547B2 (OSRAM)
EP (2) EP2865389A1 (OSRAM)
JP (4) JP5209800B2 (OSRAM)
KR (3) KR101413844B1 (OSRAM)
CN (1) CN102245198B (OSRAM)
AR (1) AR074505A1 (OSRAM)
AU (1) AU2009325950B2 (OSRAM)
BR (1) BRPI0922561A2 (OSRAM)
CA (1) CA2744754A1 (OSRAM)
CO (1) CO6561830A2 (OSRAM)
DK (1) DK2376108T3 (OSRAM)
ES (1) ES2622562T3 (OSRAM)
IL (1) IL213029A0 (OSRAM)
MX (2) MX337723B (OSRAM)
NZ (2) NZ604186A (OSRAM)
PE (2) PE20110891A1 (OSRAM)
RU (1) RU2495049C2 (OSRAM)
SG (2) SG10201400388QA (OSRAM)
TW (1) TWI387463B (OSRAM)
WO (1) WO2010067286A2 (OSRAM)
ZA (1) ZA201104072B (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9243062B2 (en) * 2005-08-11 2016-01-26 Arpi Matossian-Rogers Peptides for treatment and diagnosis of autoimmune disease
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
CA2745096C (en) 2008-12-09 2013-11-05 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
EP2575868A1 (en) * 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige ch3 peptide vaccine
EP2471926A3 (en) 2010-12-30 2012-07-11 Intervet International BV Immunostimulatory oligodeoxynucleotides
MX2013013801A (es) * 2011-05-26 2013-12-16 Intervet Int Bv Oligodesoxinucleotidos inmunoestimuladores.
BR112013029968A2 (pt) * 2011-05-26 2017-01-31 Intervet Int Bv oligodesoxinucleotídeo imunoestimulatório não metilado, vetor, vacina para prevenir ou combater uma doença infecciosa, e, método para a detecção de oligodesoxinucleotídeos imunoestimulatórios
US9956276B2 (en) 2012-01-19 2018-05-01 Duke University Vaccines against antigens involved in therapy resistance and methods of using same
US9187553B2 (en) * 2012-01-25 2015-11-17 Swey-Shen Chen Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold
WO2013191166A1 (ja) 2012-06-18 2013-12-27 日本全薬工業株式会社 IgEペプチドワクチン
WO2016007504A1 (en) 2014-07-07 2016-01-14 Duke University Vaccines against an oncogenic isoform of esr1 and methods of using the same
EP3166646A4 (en) 2014-07-07 2018-03-07 Duke University Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same
EP3166966A1 (en) 2014-07-10 2017-05-17 Affiris AG Substances and methods for the use in prevention and/or treatment in huntington's disease
MX374553B (es) * 2015-09-30 2025-03-06 Shionogi & Co Derivado de ácido nucleico que tiene actividad inmunoestimuladora.
KR101876620B1 (ko) * 2015-10-27 2018-07-09 대구한의대학교산학협력단 펩타이드 기반 분자결합자를 이용한 노로바이러스 검출칩 및 그 제작방법
WO2017120576A1 (en) 2016-01-07 2017-07-13 Duke University Cancer vaccines and methods of delivery
JP7041923B2 (ja) 2016-03-03 2022-03-25 学校法人藤田学園 大豆アレルギーの抗原
US11224665B2 (en) 2016-10-05 2022-01-18 Duke University Mitochondrial antiviral signaling (MAVS) protein compositions and methods of using the same
US10487143B2 (en) 2016-10-05 2019-11-26 Duke University Vaccines against HER3 antigens and methods of using the same
IL268983B2 (en) * 2017-03-29 2024-07-01 Shionogi & Co Nucleic acid derivative having immunostimulatory activity
EP4198058A4 (en) * 2020-08-13 2024-10-16 Nibec Co., Ltd. ANTIBODIES AGAINST INTRACELLULAR TUMOR-INDUCING PROTEIN OR FUSION PROTEIN OF A SINGLE-STRANDED VARIABLE FRAGMENT THEREOF AND CANCER CELL PENETRATING PEPTIDE AND USE THEREOF
US20230364232A1 (en) 2020-09-17 2023-11-16 Neovacs IMMUNOGENIC PRODUCT COMPRISING AN IgE FRAGMENT FOR TREATING IgE-MEDIATED INFLAMMATORY DISORDERS
US20250205331A1 (en) * 2022-03-28 2025-06-26 The Regents Of The University Of California Novel plant virus and bacteriophage vaccines

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2055131B (en) 1978-09-29 1982-12-15 Energy Secretary Of State For Electrical power transmission in fluid wells
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
ATE75483T1 (de) 1981-10-23 1992-05-15 Molecular Biosystems Inc Oligonukleotides heilmittel und dessen herstellungsverfahren.
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US5374426A (en) 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
JPS63225397A (ja) * 1986-10-03 1988-09-20 Dainippon Pharmaceut Co Ltd 抗アレルギー作用を有する新規ペプチド
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
NZ235315A (en) 1989-09-19 1991-09-25 Wellcome Found Chimaeric hepadnavirus core antigen proteins and their construction
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
US5258289A (en) * 1990-09-05 1993-11-02 Davis Claude G Method for the selecting of genes encoding catalytic antibodies
WO1992011291A1 (en) 1990-12-20 1992-07-09 Smithkline Beecham Biologicals (S.A.) Vaccines based on hepatitis b surface antigen
SE9102808L (sv) 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
EP0671948B1 (en) 1992-06-25 1997-08-13 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
DK0689454T4 (da) 1993-03-23 2005-05-30 Smithkline Beecham Biolog Vaccinepræparater indeholdende 3-O-deacyleret monophosphoryl-lipid A
DE4321946A1 (de) 1993-07-01 1995-01-12 Hoechst Ag Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5658738A (en) 1994-05-31 1997-08-19 Becton Dickinson And Company Bi-directional oligonucleotides that bind thrombin
JP3468773B2 (ja) 1994-07-15 2003-11-17 ザ ユニバーシティ オブ アイオワ リサーチ ファウンデーション 免疫調節オリゴヌクレオチド
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
CN1185811A (zh) 1995-03-31 1998-06-24 H·沃尔夫 依赖于逆转录病毒样颗粒的抗原呈递系统
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
ES2190799T5 (es) 1996-03-01 2008-08-16 Novartis Ag Inmunogenos peptidicos para vacunacion y tratamiento contra la alergia.
ID18046A (id) 1996-08-20 1998-02-19 Takeda Chemical Industries Ltd Senyawa siklik campuran, pembuatan dan penngunaannya.
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
ES2241042T3 (es) 1996-10-11 2005-10-16 The Regents Of The University Of California Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora.
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
EP1039935A4 (en) 1997-02-28 2005-04-27 Univ Iowa Res Found USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
WO1998040100A1 (en) 1997-03-10 1998-09-17 Ottawa Civic Loeb Research Institute USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT
US6339068B1 (en) 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
ATE432348T1 (de) 1997-06-06 2009-06-15 Univ California Inhibitoren von immunstimulatorischen dna sequenz aktivität
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
EP1009382B1 (en) 1997-09-05 2003-06-18 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
US6231864B1 (en) 1998-02-12 2001-05-15 Immune Complex Corporation Strategically modified hepatitis B core proteins and their derivatives
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
CA2323929C (en) 1998-04-03 2004-03-09 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
US6734287B1 (en) * 1998-04-09 2004-05-11 Idexx Laboratories, Inc. Specific binding proteins for treating canine allergy
DE69922873T2 (de) * 1998-04-09 2005-12-29 Idexx Laboratories, Inc. Spezifische Bindungsproteine zur Behandlung von Allergien beim Hund
US7393529B2 (en) * 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
EP1069910A1 (en) 1998-04-09 2001-01-24 GlaxoSmithKline Biologicals S.A. Adjuvant compositions
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
ES2233101T3 (es) 1998-09-03 2005-06-01 Chiron Corp Dosis unitaria de fgf-2 angiogenicamente efectiva y su utilizacion.
WO2000017158A1 (de) 1998-09-18 2000-03-30 Pentapharm Ag Urokinase-inhibitoren
PL201482B1 (pl) 1998-10-16 2009-04-30 Smithkline Beecham Biolog Sposoby wytwarzania kompozycji szczepionki oraz kompozycja szczepionki
JP4486257B2 (ja) 1998-10-21 2010-06-23 アメリカ合衆国 自己抗体の誘導のためのウイルス様粒子
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
EP1119630B1 (en) 1998-11-05 2006-01-11 Powderject Vaccines, Inc. Nucleic acid constructs for genetic immunisation
WO2000032227A2 (en) 1998-11-30 2000-06-08 Cytos Biotechnology Ag Ordered molecular presentation of antigens, method of preparation and use
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
NZ513935A (en) 1999-02-17 2004-02-27 Csl Ltd Immunogenic complexes and methods relating thereto
US20030170229A1 (en) * 1999-02-25 2003-09-11 Smithkline Beecham Biologicals S.A. Vaccine
CA2363641A1 (en) * 1999-02-25 2000-08-31 Smithkline Beecham Biologicals S.A. Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses
DK1163000T3 (da) 1999-03-19 2008-04-28 Glaxosmithkline Biolog Sa Vacciner imod antigener fra bakterier
JP2002539818A (ja) * 1999-03-30 2002-11-26 アイデックス ラボラトリーズ インコーポレイテッド イヌのアレルギーを治療するための特異的結合蛋白
DK1187629T3 (da) 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
PL355163A1 (en) 1999-09-24 2004-04-05 Smithkline Beecham Biologicals S.A. Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
BR0014285A (pt) 1999-09-24 2002-05-21 Smithkline Beecham Biolog Adjuvantes compreendendo um éster ou éter de alquila de polioxietileno e pelo menos um tensoativo não-iÈnico
AU783118B2 (en) 1999-09-27 2005-09-29 Coley Pharmaceutical Gmbh Methods related to immunostimulatory nucleic acid-induced interferon
WO2001077158A1 (en) 2000-04-07 2001-10-18 University Of Leeds Innovations Limited Hepatitis b core antigen fusion proteins
CA2407897A1 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
PT1294893E (pt) 2000-06-22 2006-08-31 Ucb Pharma Ltd Modificacao do antigenio nuclear de hepatite b
WO2002005690A1 (en) 2000-07-15 2002-01-24 Lighthouse Display International Limited Shelf edge display fittings
AUPQ912000A0 (en) 2000-07-31 2000-08-24 Crown In The Right Of The Queensland Department Of Health, The Improved virus like particles
US20030138769A1 (en) 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
EP2361635A3 (en) * 2000-08-30 2011-09-14 Pfizer Products Inc. Anti IgE vaccines
GB0026334D0 (en) 2000-10-27 2000-12-13 Smithkline Beecham Biolog Vaccine
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
WO2003102165A2 (en) 2002-02-21 2003-12-11 Apovia, Inc. IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE
WO2003024480A2 (en) 2001-09-14 2003-03-27 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
ES2335979T3 (es) 2001-09-14 2010-04-07 Cytos Biotechnology Ag Empaquetamiento de cpg inmunoestimuladores en particulas similares a virus: metodo de preparacion y su uso.
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
US20040176283A1 (en) 2002-04-01 2004-09-09 Robinson John A. Methods and compositions for the design of synthetic vaccines
GB0209878D0 (en) 2002-04-30 2002-06-05 Glaxosmithkline Biolog Sa Vaccine
CU22983A1 (es) * 2002-05-08 2004-09-09 Inst Finlay Composición vacunal contra las alergias y método para su obtención y empleo en el tratamiento de las mismas
CN102061288A (zh) 2002-07-17 2011-05-18 希托斯生物技术股份公司 使用衍生自ap205外壳蛋白的病毒样颗粒的分子抗原阵列
JP5070371B2 (ja) 2002-12-10 2012-11-14 サノフィ パスツール バイオロジスク カンパニー 安定化させた免疫原性ＨＢｃキメラ粒子
CA2517839A1 (en) * 2003-03-26 2004-10-07 Martin F. Bachmann Melan-a peptide analogue-virus-like-particle conjugates
KR101365375B1 (ko) 2004-02-02 2014-02-19 타녹스 인코퍼레이티드 신규한 ＩｇＥ 에피토프의 확인
AU2005335104C1 (en) 2004-07-18 2010-10-28 Csl Limited Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
EP1776105A2 (en) 2004-07-18 2007-04-25 Coley Pharmaceutical Group, Ltd Methods and compositions for inducing innate immune responses
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
GB2443591B (en) * 2005-09-07 2010-04-28 Secr Defence Adjuvanted vaccine
JP5473336B2 (ja) 2006-02-15 2014-04-16 アディウタイド・ファーマスーティカルズ・ゲーエムベーハー オリゴヌクレオチドの処方に関する組成物および方法
US20080166785A1 (en) 2006-08-16 2008-07-10 Monica Sala-Schaeffer Polynucleotides allowing the expression and secretion of recombinant HBsAg virus-like particles containing a foreign peptide, their production and use
EP2142214A4 (en) 2007-04-02 2012-03-21 Amgen Fremont Inc ANTI-IGE ANTIBODY
ES2602610T3 (es) * 2007-05-31 2017-02-21 Medigene Ag Proteína estructural mutada de un parvovirus
US9501570B2 (en) 2014-07-14 2016-11-22 Verizon Patent And Licensing Inc. Dynamic routing system
US9719791B2 (en) 2014-12-10 2017-08-01 Mapquest, Inc. Computerized systems and methods for providing travel information and/or content to users
ES2893464T3 (es) 2016-06-23 2022-02-09 Ripples Ltd Procedimiento y aparato para imprimir en una bebida

Also Published As

Publication number Publication date
US9216229B2 (en) 2015-12-22
EP2865389A1 (en) 2015-04-29
JP2016164156A (ja) 2016-09-08
RU2011121043A (ru) 2013-01-20
IL213029A0 (en) 2011-07-31
KR101413844B1 (ko) 2014-06-30
US20120294848A1 (en) 2012-11-22
MX2011006077A (es) 2011-09-01
WO2010067286A2 (en) 2010-06-17
RU2495049C2 (ru) 2013-10-10
JP2014012009A (ja) 2014-01-23
AU2009325950B2 (en) 2013-03-07
BRPI0922561A2 (pt) 2020-08-11
EP2376108A2 (en) 2011-10-19
SG10201400388QA (en) 2014-05-29
KR20130032390A (ko) 2013-04-01
US8298547B2 (en) 2012-10-30
SG186611A1 (en) 2013-01-30
JP5367137B2 (ja) 2013-12-11
CO6561830A2 (es) 2012-11-15
CN102245198A (zh) 2011-11-16
AU2009325950A1 (en) 2010-06-17
US20140017239A1 (en) 2014-01-16
KR101634058B1 (ko) 2016-06-27
KR101644221B1 (ko) 2016-07-29
ES2622562T3 (es) 2017-07-06
WO2010067286A3 (en) 2010-08-05
CN102245198B (zh) 2016-08-17
EP2376108B1 (en) 2017-02-22
NZ604186A (en) 2014-07-25
PE20110891A1 (es) 2011-12-23
MX337723B (es) 2016-03-15
ZA201104072B (en) 2012-02-29
PE20142330A1 (es) 2015-01-14
CA2744754A1 (en) 2010-06-17
HK1163511A1 (zh) 2012-09-14
NZ592977A (en) 2013-01-25
JP5209800B2 (ja) 2013-06-12
JP2012255006A (ja) 2012-12-27
KR20150056881A (ko) 2015-05-27
JP5964280B2 (ja) 2016-08-03
JP2012511322A (ja) 2012-05-24
US20100158933A1 (en) 2010-06-24
US8475801B2 (en) 2013-07-02
TW201036632A (en) 2010-10-16
AR074505A1 (es) 2011-01-19
DK2376108T3 (en) 2017-04-24
KR20110094134A (ko) 2011-08-19

Similar Documents

Publication Publication Date Title
TWI387463B (zh) Ｉｇｅ ｃｈ３肽疫苗
TWI400085B (zh) Ｐｃｓｋ９疫苗
AU2010277254B2 (en) Antigenic tau peptides and uses thereof
US8722053B2 (en) IgE CH3 peptide vaccine
AU2013204233B2 (en) IgE CH3 peptide vaccine
HK1163511B (zh) Ige ch3肽疫苗

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees